drugs

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Inc. (NYSE: ABBV) reported its fourth quarter financial results for fiscal year 2017. The pharmaceutical company reported better than expected earnings sending shares 13.5 percent before market close on Friday.For the fourth quarter, AbbVie r..

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter financial results for fiscal year 2017. The U.S. drug-maker fell short on earnings estimates, but topped revenue estimates, sending shares 3 percent higher during Thursday’s pre-marke..

Teva Pharmaceuticals to Cut 25% of Jobs

Teva Pharmaceuticals to Cut 25% of Jobs

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), based in Israel, is one of the world’s largest makers of generic drugs. The pharmaceutical giant has had a rough year, facing declining prices for generic drugs and the loss of a major branded d..

Teva May Cut 10,000 Jobs

Teva May Cut 10,000 Jobs

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced the cut of 10,000 jobs as the company aims to reduce $1.5 billion to $2 billion in costs over the next two years. Following this announcement, the drug maker’s U.S. shares increase..

Spectrum shares surge on positive results from lung cancer treatment trial

Spectrum shares surge on positive results from lung cancer treatment trial

Spectrum Pharmaceutical Inc. (NASDAQ: SPPI) shares surged over 40 percent on Tuesday at open after its announcement of positive results from its Phase 2 clinical study of poziotinib. The announcement was presented at the 18th IASLC World Conference ..

National Institute of Health partners with 11 Biopharma companies for Cancer Research

National Institute of Health partners with 11 Biopharma companies for Cancer Research

The National Institutes of Health and 11 biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT). This is a five-year-public-private research collaboration totaling $215 million as part of the Cancer Moons..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..